secwatch / observer
8-K filed June 17, 2026, 4:50 PM ET ticker ANVS CIK 0001477845
other confidence high sentiment neutral materiality 0.15

Annovis Bio stockholders elect all five director nominees and approve all proposals at 2026 annual meeting

Annovis Bio, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Annovis Bio, Inc. shareholders approved Ratification of the Company's Independent Auditors at the 2026-06-17 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
The ratification of the appointment of Ernst & Young LLP was approved by stockholders by the following vote: For Against Abstain 20,634,176 568,155 502,782
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Annovis Bio, Inc. shareholders approved Advisory (Non-Binding) Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-17 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
The compensation of the Company's named executive officers was approved b y the stockholders o n an advisory (non-binding basis), by the following vote: Broker Non-Vote For Against Abstain Broker Non-Vote 8,067,931 901,342 185,701 12,550,139
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Annovis Bio, Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
Election of Directors All of the following five nominees were elected to the Company's Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Annovis Bio, Inc. shareholders approved Amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to increase the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares at the 2026-06-17 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
The amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to i ncrease the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares, was approved by stockholders by the following vote: For Against Abstain Broker Non-Vote 8,089,891 899,671 165,409 12,550,142
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-075198
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.